National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 30877 [2017-13896]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 126 / Monday, July 3, 2017 / Notices
substance use disorder treatment,
employers, and patients or their
advocates. Written comments may be
submitted to parity@hhs.gov for two
weeks prior to the meeting through
August 10, 2017.
DATES: The meeting will be held on July
27, 2017 from 9:30 a.m. to 11:30 a.m.
EDT.
ADDRESSES: The meeting will be held in
the first floor auditorium in the Hubert
H. Humphrey Building, 200
Independence Avenue SW.,
Washington, DC 20201.
Comments: The time for oral
comments will be limited to five (5)
minutes per individual. In lieu of oral
comments, formal written comments
may be submitted for the record to
Laurel Fuller, ASPE, 200 Independence
Avenue SW., Room 424E, Washington,
DC 20201; all comments should be
submitted to parity@hhs.gov. Those
submitting comments should identify
themselves and any relevant
organizational affiliations.
FOR FURTHER INFORMATION CONTACT:
Laurel Fuller (202) 690–5949,
Laurel.Fuller@hhs.gov.
SUPPLEMENTARY INFORMATION:
Procedure and Agenda: This meeting
is open to the public. Please allow 45
minutes to go through security and walk
to the meeting room. The meeting will
also be webcast at www.hhs.gov/live.
Note: Seating will be limited to 75
attendees; this listening session will
also be webcast online at www.hhs.gov/
live. Those wishing to attend the
meeting must send an email to parity@
hhs.gov and put ‘‘July 27 Public
Meeting’’ in the Subject line by Friday,
July 21, 2017 so that their names may
be put on a list of expected attendees
and forwarded to the security officers
the Humphrey Building. In the email
please also indicate which group you
are representing (State health
commissioners, State agencies, State
attorneys general, the National
Association of Insurance
Commissioners, health insurance
issuers, providers of mental health and
substance use disorder treatment,
employers, and patients or their
advocates; or other). Any interested
member of the public who is a non-U.S.
citizen should include this information
at the time of registration to ensure that
the appropriate security procedure to
gain entry to the building is carried out.
Although the meeting is open to the
public, procedures governing security
and the entrance to federal buildings
may change without notice. If you wish
to make a public comment, you must
note that within your email.
Authority: 114–255 Pub. L. 114–255.
VerDate Sep<11>2014
17:53 Jun 30, 2017
Jkt 241001
Dated: June 26, 2017.
John R. Graham,
Acting Assistant Secretary for Planning and
Evaluation.
[FR Doc. 2017–13959 Filed 6–30–17; 8:45 am]
BILLING CODE 4150–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Review of K24
Application.
Date: July 25, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Barbara A. Woynarowska,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 754, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
402–7172, woynarowskab@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–16–127:
NIDDK Program Projects (P01).
Date: August 7, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A. Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
PO 00000
Frm 00062
Fmt 4703
Sfmt 9990
30877
Special Emphasis Panel; Limited
Competition: Data Coordinating Center for
Type 1 Diabetes TrialNet (UC4).
Date: August 15, 2017.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: June 27, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–13896 Filed 6–30–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel, July
12, 2017, 11:00 a.m. to July 12, 2017,
3:00 p.m., National Cancer Institute
Shady Grove, Shady Grove, 9609
Medical Center Drive, 7W114,
Rockville, MD 20850 which was
published in the Federal Register on
May 31, 2017, 82 FR 24983.
The meeting notice is amended to
change the meeting title to
‘‘Biospecimen and Innovative
Technology’’. The meeting is closed to
the public.
Dated: June 27, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–13895 Filed 6–30–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 82, Number 126 (Monday, July 3, 2017)]
[Notices]
[Page 30877]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-13896]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Review of K24
Application.
Date: July 25, 2017.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Barbara A. Woynarowska, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
402-7172, woynarowskab@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR-16-127: NIDDK
Program Projects (P01).
Date: August 7, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ann A. Jerkins, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-
594-2242, jerkinsa@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Limited Competition:
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4).
Date: August 15, 2017.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Paul A. Rushing, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8895, rushingp@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: June 27, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-13896 Filed 6-30-17; 8:45 am]
BILLING CODE 4140-01-P
